Global Cancer Cachexia Market - 2022-2029

Market Overview

The Global "Cancer Cachexia Market" is expected to grow at a CAGR of 5.2% during the forecasting period (2022-2029).

Cancer cachexia is a wasting syndrome characterized by weight loss, anorexia, asthenia, and anemia. The pathogenicity of this syndrome is multifactorial, due to a complex interaction of tumor and host factors. The signs and symptoms of cachexia are considered the prognostic parameters in cancer patients. The pathogenicity of this syndrome is multifactorial due to a complex interaction of tumor and host factors. Cancer cachexia drugs are used to treat or alleviate the condition.

Market Dynamics

The global cancer cachexia market growth is driven by the expansion in the prevalence of serious health conditions, for instance, cancer, and the rising number of cachexia among these patients. This is further supported by the increasing awareness amongst consumers regarding the availability of novel therapeutic drugs to treat cancer cachexia.

The strong R&D and product pipeline will drive the market growth

Most of the major players are focused on R&D activities to develop highly effective novel drugs in the treatment of cancer cachexia. This factor resulted in an increased pipeline of therapeutics waiting for approval and commercial launch post-approval. For instance, clinicaltrials.gov reported that, as of February 7, 2022, a total of 141 studies were conducted or were being conducted to develop drugs that treat cancer cachexia.

The current treatment options for cachexia among cancer patients are limited to drugs namely, progestogens, corticosteroids, and others. These drugs have proved their efficiency in the treatment of cancer-induced cachexia, although there is a clinical gap in the treatment outcomes. At present, there is no drug candidate is specifically approved for the treatment of this condition. This augments the gap in treatment options, which the market players are aiming to fulfill through R&D and the introduction of new drugs in the global market. For instance, PF-06946860, which is being sponsored by Pfizer Inc., is currently in Phase 1 of clinical trials. The purpose of this trial is to study the efficacy of PF-06946860 in the treatment of non-small cell lung cancer (NSCLC) patients with cachexia. The success of the clinical trials of new candidates, regulatory approvals, and introductions of these drugs are anticipated to further boost the demand and adoption among the healthcare providers of cancer cachexia therapeutics.

High costs associated with treatment and stringent government policies to restrict growth will hamper the growth of the market

Despite the rising prevalence of cancer cachexia globally, certain factors are limiting the growth of the overall market. Among them is the high cost associated with cancer and its supportive treatment, as well as limited reimbursement for the therapeutics in the emerging countries. It is estimated that the cost associated with the treatment of cancer patients suffering from cachexia is comparatively higher than that of non-cachexia cancer patients. Also, stringent government regulations regarding the clinical trial of new candidates have been one of the major barriers to the development and approval of an effective treatment for this disorder. Thus, the higher out-of-pocket expenditure associated with cancer-induced cachexia and the lack of approved products for treatment is expected to contribute to the slow growth of this market during the forecast period.

COVID-19 Impact Analysis

The COVID-19 outbreak impacted the cancer cachexia market, as hospitals and healthcare services were significantly reduced due to social distancing measures enforced globally. The COVID-19 pandemic also affected the global economy and impacted the general hospital care functioning for non-COVID-19 patients in hospitals worldwide.

According to a research article published in the British Journal of Nutrition, 2020, changes in the nutritional status and weight loss during hospitalization are largely reported in some populations. However, it is not completely explored in COVID-19 patients. However, the symptoms and associated conditions of COVID-19 deteriorate nutritional status, leading to cachexia.

Cancer patients are at a higher risk of being infected with COVID-19, as they are immunocompromised and their ability to fight against the infection is very low compared to other individuals. Additionally, if a cancer patient develops a COVID-19 infection, there are higher chances of developing multiple organ-related complications or cachexia.

Segment Analysis

The appetite stimulators segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Cancer patients frequently develop loss of appetite and weight loss. Unintended weight loss and anorexia (the loss of appetite or desire to eat) in patients with cancer is associated with decreased performance status, reduced response and tolerance to treatment, decreased survival, and reduced quality of life. Therefore, the increasing use of an appetite stimulant could be considered for patients who exhibit decreased appetite. The increasing prevalence of cancer cachexia cases is one of the major factors propelling the overall market's growth.

According to the Oncology Nursing Society, appetite stimulants such as dexamethasone, methylprednisolone, prednisolone, megestrol acetate, and medroxyprogesterone acetate have been shown to increase the appetite and weight of patients suffering from cancer cachexia. Megestrol acetate is an appetite stimulant with progestational and antigonadotropic effects. In cancer patients with weight loss, megestrol acetate has been reported to have beneficial effects on appetite and a slight increase in weight. However, it has not improved lean body mass or quality of life. Thus, its demand is expected to increase with the increasing diagnosis of cancers.

Therefore, with the growing burden of cancer worldwide, market players are investing steadily in innovative products and their R&D, thus boosting the market's growth. For instance, in March 2020, Pfizer Inc., a global pharmaceutical major, launched a global 12-week open-label study that will explore how its drug, PF-06946860, is tolerated in patients with cancer cachexia. Hence, such factors may help the appetite stimulators segment will drive the growth of the market.

Geographical Analysis

North America region holds the largest market share of the global cancer cachexia market

North America dominates the market for cancer cachexia and is expected to show a similar trend over the forecast period, owing to the presence of many drug manufacturers, and the advancing paradigm of care for cancer patients. According to the estimates of GLOBOCAN 2020, there are around 195,499 new cases of cancer in Mexico. At the same time, approximately 90,222 cancer-related deaths were recorded in 2020 in Mexico.

According to Markus S. Anker, in the article titled "Orphan Disease Status of Cancer Cachexia in the USA and the European Union: A Systematic Review", published in 2019, in the 14 separately analyzed cancer types, the prevalence of cancer cachexia in the United States ranged between 11,300 (0.4/10 000, gastric cancer) and 92,000 patients (2.9/10000, lung cancer).

Advancements in novel technology for the treatment of cancer cachexia and a strong product pipeline for wasting syndrome have also helped in the growth of the cancer cachexia market in the region. Aveo Oncology, a US-based biopharmaceutical company, developed AV-380, a first-in-class, potent, and humanized inhibitory antibody targeting GDF15, to treat cancer cachexia. The product is on track for IND application submission, with the Phase 1 clinical study in Q1 2021. Thus, due to such factors, the market is expected to grow in the region.

Competitive Landscape

The cancer cachexia market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Aeterna Zentaris, Aphios Corporation, Bristol-Myers Squibb Company, Pfizer Inc., Helsinn Group, Merck KgaA, Artelo Biosciences Inc., NGM Biopharmaceuticals, Aveo Oncology, Aavogen Inc. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the cancer Cachexia Market globally. For instance, in February 2021, Artelo Biosciences Inc. collaborated with researchers from Trinity College Dublin to investigate pre-clinical models of human cancer cachexia.

Bristol-Myers Squibb Company

Overview:

Bristol-Myers Squibb Company discovers, develops, licenses manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases.

Product Portfolio:

Megace: MEGACE (megestrol acetate, USP) Oral Suspension contains megestrol acetate, a synthetic derivative of the steroid hormone, progesterone. MEGACE Oral Suspension is supplied as an oral suspension containing 40 mg of micronized megestrol acetate per mL.

Why Purchase the Report?

• Visualize the composition of the global cancer cachexia market segmentation by therapeutics, mechanism, distribution channel, and region highlighting the key commercial assets and players.

• Identify commercial opportunities in the global cancer cachexia market by analyzing trends and co-development deals.

• Excel data sheet with thousands of data points of global cancer cachexia market-level 4/5 segmentation.

• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

• Product mapping in excel for the key product of all major market players

The global cancer cachexia market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 195 (approximate) pages.